The Delhi High Court has set aside seven tax tribunal orders involving Patanjali Ayurved, citing procedural errors. The court ordered a fresh hearing, extending the period of uncertainty regarding the company's past tax liabilities. While this concerns the unlisted entity, investors of the group's listed arm, Patanjali Foods, continue to monitor broader corporate developments and recent financial results.
The Delhi High Court has invalidated seven orders issued by the Income Tax Appellate Tribunal (ITAT) concerning tax assessments for Patanjali Ayurved Limited. In a sharp critique of the proceedings, the court described the tribunal’s handling of these matters as reckless, citing significant procedural flaws and inconsistent record-keeping.
The dispute centers on the integrity of the judicial process. The High Court identified a major chronological error, noting that the tribunal had consolidated appeals heard on two separate dates—August 6 and August 13, 2025—into a single, common order. This approach was labeled a failure of judicial rigor, leading the court to conclude that the tribunal did not properly review or address the specific contentions raised by the parties involved. As a result, the court has directed that all seven matters be reheard in their entirety by a different bench of the tribunal.
For investors, it is important to distinguish between Patanjali Ayurved Limited, which is the private entity involved in this tax dispute, and Patanjali Foods Limited, the listed entity on the stock exchanges. While the legal proceedings are specific to the unlisted entity’s tax assessments for the assessment years 2013-14 through 2015-16 and 2017-18, the group's overall corporate governance and legal history remain a point of interest for the market.
Patanjali Foods Limited, which operates the group's listed consumer business, recently reported its financial performance for the first quarter of the 2027 fiscal year. The company showed a 27% year-on-year increase in revenue to ₹113.4 billion, with net profit rising by 87% to ₹3.36 billion. Despite this growth, the stock has faced volatility in recent months, with some market analysts pointing to valuation concerns relative to profit margins.
The primary risk arising from this court order is the continued uncertainty regarding tax liabilities for Patanjali Ayurved. Until the fresh hearings are completed and the new tribunal bench reaches a conclusion, the final tax impact remains unknown. Investors often watch such developments to assess whether they may affect the broader group's financial flexibility or operational focus. The next important update to track will be the timeline for the fresh rehearing process mandated by the High Court.